surmount-osa trial tirzepatide results for the Treatment of Obstructive Sleep Apnea and Obesity New GLP-1 clinical trial data
Pay in 4 interest-free payments of $5.73 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
Live Spec
New GLP 1 clinical trial data validates Truveta real world data study Excess adiposity is a reversible etiologic risk factor for obstructive sleep apnea. In a new trial, tirzepatide reduced the apnea hypopnea index of participants with obstructive sleep apnea and obesity. Read the In the two SURMOUNT OSA trials, researchers assessed the efficacy and safety of tirzepatide for the treatment of adults with obstructive sleep apnea and obesity. Full results of both trials and Plain Language SURMOUNT 1 Trial Cardionerds Twitter Journal Club Tirzepatide shows dual benefits in sleep apnea trial improving metabolism and reducing inflammation Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity @NEJM https: t.co RKdvTJxd7Y #ADA2024
Store: www.ab-travaux.com · Domain: www.ab-travaux.com





























